BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Elhadad S, Chapin J, Copertino D, Van Besien K, Ahamed J, Laurence J. MASP2 levels are elevated in thrombotic microangiopathies: association with microvascular endothelial cell injury and suppression by anti-MASP2 antibody narsoplimab. Clin Exp Immunol 2021;203:96-104. [PMID: 32681658 DOI: 10.1111/cei.13497] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Götz MP, Skjoedt MO, Bayarri-Olmos R, Hansen CB, Pérez-Alós L, Jarlhelt I, Benfield T, Rosbjerg A, Garred P. Lectin Pathway Enzyme MASP-2 and Downstream Complement Activation in COVID-19. J Innate Immun 2022;:1-14. [PMID: 35816998 DOI: 10.1159/000525508] [Reference Citation Analysis]
2 Meri S, Bunjes D, Cofiell R, Jodele S. The Role of Complement in HSCT-TMA: Basic Science to Clinical Practice. Adv Ther 2022. [PMID: 35781192 DOI: 10.1007/s12325-022-02184-4] [Reference Citation Analysis]
3 Elhadad S, Chadburn A, Magro C, Van Besien K, Roberson EDO, Atkinson JP, Terry H, Greenberg J, Reid W, Chapin J, Copertino D, Geramfard S, Rodriguez LB, Orfali N, Gerghis U, Shore T, Mayer S, Ahamed J, Laurence J. C5b-9 and MASP2 deposition in skin and bone marrow microvasculature characterize hematopoietic stem cell transplant-associated thrombotic microangiopathy. Bone Marrow Transplant. [DOI: 10.1038/s41409-022-01723-5] [Reference Citation Analysis]
4 Blasco M, Guillén-Olmos E, Diaz-Ricart M, Palomo M. Complement Mediated Endothelial Damage in Thrombotic Microangiopathies. Front Med (Lausanne) 2022;9:811504. [PMID: 35547236 DOI: 10.3389/fmed.2022.811504] [Reference Citation Analysis]
5 Meuleman MS, Duval A, Fremeaux-Bacchi V, Roumenina LT, Chauvet S. Ex Vivo Test for Measuring Complement Attack on Endothelial Cells: From Research to Bedside. Front Immunol 2022;13:860689. [PMID: 35493497 DOI: 10.3389/fimmu.2022.860689] [Reference Citation Analysis]
6 Heja D, Zhao D, Cody E, Cumpelik A, Lim PC, Prado-acosta M, Palma L, Dellepiane S, Chun N, Ferrara J, Heeger PS. Mannan binding lectin promotes murine graft versus host disease by amplifying lipopolysaccharide-initiated inflammation. Transplantation and Cellular Therapy 2022. [DOI: 10.1016/j.jtct.2022.05.031] [Reference Citation Analysis]
7 Khaled SK, Claes K, Goh YT, Kwong YL, Leung N, Mendrek W, Nakamura R, Sathar J, Ng E, Nangia N, Whitaker S, Rambaldi A; OMS721-TMA-001 Study Group Members. Narsoplimab, a Mannan-Binding Lectin-Associated Serine Protease-2 Inhibitor, for the Treatment of Adult Hematopoietic Stem-Cell Transplantation-Associated Thrombotic Microangiopathy. J Clin Oncol 2022;:JCO2102389. [PMID: 35439028 DOI: 10.1200/JCO.21.02389] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
8 Milone G, Bellofiore C, Leotta S, Milone GA, Cupri A, Duminuco A, Garibaldi B, Palumbo G. Endothelial Dysfunction after Hematopoietic Stem Cell Transplantation: A Review Based on Physiopathology. J Clin Med 2022;11:623. [PMID: 35160072 DOI: 10.3390/jcm11030623] [Reference Citation Analysis]
9 Gavriilaki E, Ho VT, Schwaeble W, Dudler T, Daha M, Fujita T, Jodele S. Role of the lectin pathway of complement in hematopoietic stem cell transplantation-associated endothelial injury and thrombotic microangiopathy. Exp Hematol Oncol 2021;10:57. [PMID: 34924021 DOI: 10.1186/s40164-021-00249-8] [Reference Citation Analysis]
10 Lim MS, Mcrae S. COVID-19 and immunothrombosis: Pathophysiology and therapeutic implications. Crit Rev Oncol Hematol 2021;168:103529. [PMID: 34800652 DOI: 10.1016/j.critrevonc.2021.103529] [Reference Citation Analysis]
11 Schoettler M, Chonat S, Williams K, Lehmann L. Emerging therapeutic and preventive approaches to transplant-associated thrombotic microangiopathy. Curr Opin Hematol 2021;28:408-16. [PMID: 34534983 DOI: 10.1097/MOH.0000000000000687] [Reference Citation Analysis]
12 Muri L, Ispasanie E, Schubart A, Thorburn C, Zamurovic N, Holbro T, Kammüller M, Pluschke G. Alternative Complement Pathway Inhibition Abrogates Pneumococcal Opsonophagocytosis in Vaccine-Naïve, but Not in Vaccinated Individuals. Front Immunol 2021;12:732146. [PMID: 34707606 DOI: 10.3389/fimmu.2021.732146] [Reference Citation Analysis]
13 Ispasanie E, Muri L, Schubart A, Thorburn C, Zamurovic N, Holbro T, Kammüller M, Pluschke G. Alternative Complement Pathway Inhibition Does Not Abrogate Meningococcal Killing by Serum of Vaccinated Individuals. Front Immunol 2021;12:747594. [PMID: 34691058 DOI: 10.3389/fimmu.2021.747594] [Reference Citation Analysis]
14 Alhomoud M, Williams A, Magro C, Van Besien K, Vesole DH, Laurence J. Use of eculizumab in autologous hematopoietic stem cell transplantation-associated thrombotic microangiopathy in two adults. Leuk Lymphoma 2021;:1-5. [PMID: 34668824 DOI: 10.1080/10428194.2021.1992625] [Reference Citation Analysis]
15 Jalink M, de Boer ECW, Evers D, Havinga MQ, Vos JMI, Zeerleder S, de Haas M, Jongerius I. Halting targeted and collateral damage to red blood cells by the complement system. Semin Immunopathol 2021. [PMID: 34191092 DOI: 10.1007/s00281-021-00859-8] [Reference Citation Analysis]
16 Ng N, Powell CA. Targeting the Complement Cascade in the Pathophysiology of COVID-19 Disease. J Clin Med 2021;10:2188. [PMID: 34069355 DOI: 10.3390/jcm10102188] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
17 Li Q, Chen Z. An update: the emerging evidence of complement involvement in COVID-19. Med Microbiol Immunol. 2021;1-9. [PMID: 33811541 DOI: 10.1007/s00430-021-00704-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Varelas C, Tampaki A, Sakellari I, Anagnostopoulos Α, Gavriilaki E, Vlachaki E. Complement in Sickle Cell Disease: Are We Ready for Prime Time? J Blood Med 2021;12:177-87. [PMID: 33790681 DOI: 10.2147/JBM.S287301] [Reference Citation Analysis]
19 Bumiller-Bini V, de Freitas Oliveira-Toré C, Carvalho TM, Kretzschmar GC, Gonçalves LB, Alencar NM, Gasparetto Filho MA, Beltrame MH, Winter Boldt AB. MASPs at the crossroad between the complement and the coagulation cascades - the case for COVID-19. Genet Mol Biol 2021;44:e20200199. [PMID: 33729332 DOI: 10.1590/1678-4685-GMB-2020-0199] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Kaplon H, Reichert JM. Antibodies to watch in 2021. MAbs 2021;13:1860476. [PMID: 33459118 DOI: 10.1080/19420862.2020.1860476] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 35.0] [Reference Citation Analysis]
21 Agostinis C, Balduit A, Mangogna A, Zito G, Romano F, Ricci G, Kishore U, Bulla R. Immunological Basis of the Endometriosis: The Complement System as a Potential Therapeutic Target. Front Immunol 2020;11:599117. [PMID: 33505394 DOI: 10.3389/fimmu.2020.599117] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
22 Laurence J, Mulvey JJ, Seshadri M, Racanelli A, Harp J, Schenck EJ, Zappetti D, Horn EM, Magro CM. Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19. Clin Immunol 2020;219:108555. [PMID: 32771488 DOI: 10.1016/j.clim.2020.108555] [Cited by in Crossref: 46] [Cited by in F6Publishing: 37] [Article Influence: 23.0] [Reference Citation Analysis]